Sign in Subscribe
Pharmaceutical industry

Sandoz Sues FDA Over Delayed Decision on Human Growth Hormone Generic

Strategic Insights

— 1 min read

Sandoz, the generic arm of Swiss pharmaceutical company Novartis, has taken legal action against the US Food and Drug Administration over its delayed decision on the company's generic human growth hormone product, Omnitrope. The product was filed for approval in July 2003, but the FDA has yet to make a decision, citing scientific and legal issues. Sandoz claims that the FDA has failed to act on the application in accordance with federal law and is seeking to reverse this decision in US District Court for the District of Columbia.

Key Takeaways:

  • Sandoz filed a New Drug Application (NDA) for Omnitrope, a generic human growth hormone product, in July 2003.
  • The FDA has yet to make a decision on the application, citing scientific and legal issues, despite the agency's obligation to approve or reject NDAs within a certain timeframe.
  • Sandoz's lawsuit claims that the FDA staff has informed the company that Omnitrope is safe and effective, and that it is indistinguishable from Pfizer's Genotropin.
  • The FDA was previously informed that Omnitrope was safe and effective, but has repeatedly failed to act on the application.
  • Pfizer filed a Citizen Petition with the FDA in May 2004, calling for the rejection of Omnitrope's application.
  • Sandoz CEO Andreas Rummelt believes that cost-effective generic alternatives like Omnitrope are essential for patients and healthcare providers.
  • The lawsuit seeks to reverse the FDA's failure to act on the Omnitrope application in accordance with federal law.

Statistics:

  • 2003: Sandoz filed a New Drug Application (NDA) for Omnitrope in July.
  • September 2004: Sandoz announced that the FDA had sent a letter stating that it was unable to reach a decision on the NDA due to scientific and legal issues.
  • May 13, 2004: Pfizer filed a Citizen Petition with the FDA, requesting the rejection of Omnitrope's application.
  • Number of years the FDA has delayed its decision on the Omnitrope application: 7 years (as of 2010).

Sources:

  • Marketletter, September 13, 2004
  • [Note: No additional source mentioned in the original text.]

Read more